Pharmacokinetics and tolerability of single ascending doses of AP 301 in male volunteers

Trial Profile

Pharmacokinetics and tolerability of single ascending doses of AP 301 in male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2014

At a glance

  • Drugs Solnatide (Primary)
  • Indications Acute lung injury; Adult respiratory distress syndrome; Pulmonary oedema; Reperfusion injury
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors APEPTICO Forschung und Entwicklung
  • Most Recent Events

    • 11 Apr 2014 New trial record
    • 01 Mar 2014 Results published in the Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top